Skip to main content
. 2013 Jan 24;8(1):e52950. doi: 10.1371/journal.pone.0052950

Table 2. Nevirapine plasma concentrations during follow-up 48 weeks.

2W 4W 12W 24W 36W 48W
n 290 270 247 244 233 226
Ctrough (µg/mL) 4.26 (IQR 3.05–5.61) 5.90 (IQR 4.54–8.14) 6.21 (IQR 4.68–8.15) 6.23 (IQR 4.56–8.47) 6.15 (IQR 4.51–8.07) 6.37 (IQR 4.72–8.64)
n 167 159 137 129 126 120
Cmax (µg/mL) 5.07(IQR 3.92–6.44) 6.89 (IQR 5.23–8.84) 6.34 (IQR 4.72–8.03) 6.32 (IQR 5.40–7.85) 6.48 (IQR 5.19–8.35) 6.91 (IQR 5.49–8.56)

Ctrough: trough concentration of nevirapine.

Cmax: peak concentration of nevirapine.

Data were described as median (IQR: inter-quartile range).